Scholarlink

<p>Immune checkpoint inhibitors (ICIs) represent a class of novel anticancer agents that enhance T cell-mediated recognition and elimination of tumor cells by inhibiting immune checkpoints such as CTLA-4 and PD-1/PD-L1. These therapeutics are widely employed in the treatment of various malignancies, including melanoma and non-small cell lung cancer, and have markedly improved clinical outcomes. However, ICIs are associated with immune-related adverse events (irAEs). Among these, cardiovascular toxicities, though relatively uncommon (occurring in approximately 3.1% of patients receiving monotherapy and 5.8% on combination therapy), are linked with the highest mortality rates. Cardiovascular toxicities associated with ICIs mainly encompass myocarditis (incidence: 1%–2%; mortality: 39.7%–66.0%), pericarditis (case fatality rate: ~13%), and accelerated atherosclerosis. Risk profiles differ across ICI agents; CTLA-4 inhibitors, for example, demonstrate more pronounced and dose-dependent cardiotoxicity, and combination therapies are associated with higher risks compared to monotherapy. The pathogenic mechanisms are attributed to loss of immune tolerance, which involves excessive activation of T cells, triggering autoimmune responses; cross-reactive T cells targeting shared cardiac antigens; and cytokine release storms that promote systemic inflammation. Although advances have been made in the diagnosis and management of cardiovascular toxicities associated with ICIs, several challenges persist. These include an incomplete understanding of the underlying mechanisms and a lack of reliable predictive biomarkers. Research should prioritize elucidating the pathogenic pathways, refining combination therapy regimens, identifying novel therapeutic targets, and developing artificial intelligence (AI)-based predictive models. Such efforts are crucial in mitigating toxicity, enhancing patients’ quality of life, and improving long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune Checkpoint Inhibitor–Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Zhengyu Chen,
  • Meijie Zheng,
  • Yuxuan Li,
  • Xiwu Zhang,
  • Jinjin Dou

摘要

Immune checkpoint inhibitors (ICIs) represent a class of novel anticancer agents that enhance T cell-mediated recognition and elimination of tumor cells by inhibiting immune checkpoints such as CTLA-4 and PD-1/PD-L1. These therapeutics are widely employed in the treatment of various malignancies, including melanoma and non-small cell lung cancer, and have markedly improved clinical outcomes. However, ICIs are associated with immune-related adverse events (irAEs). Among these, cardiovascular toxicities, though relatively uncommon (occurring in approximately 3.1% of patients receiving monotherapy and 5.8% on combination therapy), are linked with the highest mortality rates. Cardiovascular toxicities associated with ICIs mainly encompass myocarditis (incidence: 1%–2%; mortality: 39.7%–66.0%), pericarditis (case fatality rate: ~13%), and accelerated atherosclerosis. Risk profiles differ across ICI agents; CTLA-4 inhibitors, for example, demonstrate more pronounced and dose-dependent cardiotoxicity, and combination therapies are associated with higher risks compared to monotherapy. The pathogenic mechanisms are attributed to loss of immune tolerance, which involves excessive activation of T cells, triggering autoimmune responses; cross-reactive T cells targeting shared cardiac antigens; and cytokine release storms that promote systemic inflammation. Although advances have been made in the diagnosis and management of cardiovascular toxicities associated with ICIs, several challenges persist. These include an incomplete understanding of the underlying mechanisms and a lack of reliable predictive biomarkers. Research should prioritize elucidating the pathogenic pathways, refining combination therapy regimens, identifying novel therapeutic targets, and developing artificial intelligence (AI)-based predictive models. Such efforts are crucial in mitigating toxicity, enhancing patients’ quality of life, and improving long-term outcomes.